Original language | English |
---|---|
Pages (from-to) | 738-739 |
Number of pages | 2 |
Journal | JAMA Psychiatry |
Volume | 79 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JAMA Psychiatry, Vol. 79, No. 7, 07.2022, p. 738-739.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Associating Violence With Schizophrenia - Risks and Biases
AU - Fusar-Poli, Paolo
AU - Sunkel, Charlene
AU - Patel, Vikram
N1 - Funding Information: EMA Wellness, Engrail Therapeutics, Clexio, Denovo Biopharma, Gilgamesh, Hoffmann La-Roche, Intra-Cellular Therapies, Janssen Pharmaceuticals, Levo, Lundbeck, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. Dr Sanacora also reported receiving research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Usona over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals and is a co-inventor on a US patent (8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application 047162-7177P1 (00754) filed on August 20, 2018, by the Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may in the future receive financial benefits from this relationship. The university has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office. Dr Wilkinson reported receiving contract funding from Janssen Pharmaceuticals, Sage Therapeutics, and Oui Therapeutics for the conduct of clinical trials administered through Yale University as well as consulting fees from Biohaven Pharmaceuticals, Sage Therapeutics, Janssen Pharmaceuticals, and Oui Therapeutics. No other disclosures were reported. Funding Information: Funding/Support: There was no direct funding for this study. However, the Yale Psychiatric Hospital provided indirect funding that allowed the Interventional Psychiatric Service to treat patients with ketamine in a clinical setting before most third-party payers began reimbursing for this service. In addition, funding through support was provided in part by the George D. Gross and Esther S. Gross Endowment (Dr Sanacora) and the Yale New Haven Health System (Drs Nikayin, Sanacora, and Wilkinson).
PY - 2022/7
Y1 - 2022/7
UR - http://www.scopus.com/inward/record.url?scp=85129886103&partnerID=8YFLogxK
U2 - 10.1001/jamapsychiatry.2022.0939
DO - 10.1001/jamapsychiatry.2022.0939
M3 - Letter
AN - SCOPUS:85129886103
SN - 2168-622X
VL - 79
SP - 738
EP - 739
JO - JAMA Psychiatry
JF - JAMA Psychiatry
IS - 7
ER -